Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

NCT06796998 is registered in ClinicalTrials.gov with Izidore Lossos, MD as lead sponsor.

NCT NCT06796998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06796998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
Lead sponsor
Izidore Lossos, MD
Phase
Phase 2
Overall status
Recruiting
Start date
October 13, 2025
Completion date
April 15, 2031
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, marginal zone lymphoma, nodal marginal zone lymphoma, splenic marginal zone lymphoma